Through its Alexion subsidiary, AstraZeneca is acquiring Lexington, Mass.-based LogicBio Therapeutics in a deal worth $68 million. The deal bolsters AstraZeneca’s efforts in genomics and rare diseases.
https://www.pharmalive.com/wp-content/uploads/2022/04/BioSpaceAstraZenecaflags4282022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-03 10:09:292022-10-03 10:09:29AstraZeneca acquires LogicBio for $68 million to bolster genomics pipeline